tradingkey.logo

ImmunityBio: Median Overall Survival Unreached, Lymphopenia Reversed In Recurrent Glioblastoma On Anktiva And CAR-NK Chemo-Free Therapy

ReutersJan 23, 2026 12:09 PM

- Immunitybio Inc IBRX.O:

  • IMMUNITYBIO REPORTS MEDIAN OVERALL SURVIVAL NOT YET REACHED AND LYMPHOPENIA REVERSED IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING ANKTIVA® PLUS CAR-NK, CHEMO-FREE THERAPY

  • IMMUNITYBIO INC: THREE PARTICIPANTS EXPERIENCED SERIOUS ADVERSE EVENTS SUSPECTED TO BE RELATED TO EXPERIMENTAL THERAPY

  • IMMUNITYBIO INC: TREATMENT REGIMEN DEMONSTRATED A MANAGEABLE SAFETY PROFILE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI